Lung adenocarcinoma: development of nomograms based on PET/CT images for prediction of epidermal growth factor receptor mutation status and subtypes

被引:2
|
作者
Huang, Lele [1 ,2 ,3 ,4 ,5 ]
Cao, Yuntai [6 ]
Zhou, Fei [7 ]
Li, Jicheng [2 ,8 ]
Ren, Jialiang [9 ]
Zhang, Guojin [10 ]
Luo, Yongjun [1 ,2 ,3 ,4 ,5 ]
Liu, Jiangyan [2 ,4 ,5 ]
He, Jiangping [11 ]
Zhou, Junlin [1 ,4 ,5 ]
机构
[1] Lanzhou Univ, Hosp 2, Dept Radiol, Cuiyingmen 82, Lanzhou 730030, Peoples R China
[2] Lanzhou Univ, Hosp 2, Dept Nucl Med, Lanzhou, Peoples R China
[3] Lanzhou Univ, Clin Sch 2, Lanzhou, Peoples R China
[4] Key Lab Med Imaging Gansu Prov, Lanzhou, Peoples R China
[5] Gansu Int Sci & Technol Cooperat Base Med Imaging, Lanzhou, Peoples R China
[6] Qinghai Univ, Affiliated Hosp, Dept Radiol, Xining, Peoples R China
[7] Gansu Univ Chinese Med, Sch Informat Sci & Engn, Lanzhou, Peoples R China
[8] Lanzhou Univ, Sch Publ Hlth, Lanzhou, Peoples R China
[9] GE Healthcare, Dept Pharmaceut Diag, Beijing, Peoples R China
[10] Sichuan Acad Med Sci, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[11] Lanzhou Univ Finance & Econ, Dept Elect Engn, Lanzhou, Peoples R China
关键词
F-18-FDG PET; CT; epidermal growth factor receptor; lung adenocarcinoma; mutation; nomogram; EGFR-MUTATION; 1ST-LINE TREATMENT; OPEN-LABEL; METABOLIC PARAMETERS; SURVIVAL-DATA; CANCER; AFATINIB; CHEMOTHERAPY; GEFITINIB; KRAS;
D O I
10.1097/MNM.0000000000001519
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To develop nomograms that combine clinical characteristics, computed tomographic (CT) features and F-18-fluorodeoxyglucose PET (F-18-FDG PET) metabolic parameters for individual prediction of epidermal growth factor receptor (EGFR) mutation status and exon 19 deletion mutation and exon 21 point mutation (21 L858R) subtypes in lung adenocarcinoma. Methods In total 124 lung adenocarcinoma patients who underwent EGFR mutation testing and whole-body F-18-FDG PET/CT were enrolled. Each patient's clinical characteristics (age, sex, smoking history, etc.), CT features (size, location, margins, etc.) and four metabolic parameters (SUVmax, SUVmean, MTV and TLG) were recorded and analyzed. Logistic regression analyses were performed to screen for significant predictors of EGFR mutation status and subtypes, and these predictors were presented as easy-to-use nomograms. Results According to the results of multiple regression analysis, three nomograms for individualized prediction of EGFR mutation status and subtypes were constructed. The area under curve values of three nomograms were 0.852 (95% CI, 0.783-0.920), 0.857 (95% CI, 0.778-0.937) and 0.893 (95% CI, 0.819-0.968) of EGFR mutation vs. wild-type, 19 deletion mutation vs. wild-type and 21 L858R vs. wild-type, respectively. Only calcification showed significant differences between the EGFR 19 deletion and 21 L858R mutations. Conclusion EGFR 21 L858R mutation was more likely to be nonsolid texture with air bronchograms and pleural retraction on CT images. And they were more likely to be associated with lower FDG metabolic activity compared with those wild-types. The sex difference was mainly caused by the 19 deletion mutation, and calcification was more frequent in them.
引用
收藏
页码:310 / 322
页数:13
相关论文
共 50 条
  • [31] FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma
    Ishimura, Mariko
    Norikane, Takashi
    Mitamura, Katsuya
    Yamamoto, Yuka
    Manabe, Yuri
    Murao, Mitsumasa
    Murota, Makiko
    Kanaji, Nobuhiro
    Nishiyama, Yoshihiro
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [32] Comparison of the radiomics-based predictive models using machine learning and nomogram for epidermal growth factor receptor mutation status and subtypes in lung adenocarcinoma
    Yusuke Kawazoe
    Takehiro Shiinoki
    Koya Fujimoto
    Yuki Yuasa
    Tsunahiko Hirano
    Kazuto Matsunaga
    Hidekazu Tanaka
    Physical and Engineering Sciences in Medicine, 2023, 46 : 395 - 403
  • [33] EGFR Mutation Status and Subtypes Predicted by CT-Based 3D Radiomic Features in Lung Adenocarcinoma
    Chen, Quan
    Li, Yan
    Cheng, Qiguang
    Van Valkenburgh, Juno
    Sun, Xiaotian
    Zheng, Chuansheng
    Zhang, Ruiguang
    Yuan, Rong
    ONCOTARGETS AND THERAPY, 2022, 15 : 597 - 608
  • [34] Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients
    Cao, Pingdong
    Jia, Xiao
    Wang, Xi
    Fan, Liyuan
    Chen, Zheng
    Zhao, Yuanyuan
    Zhu, Jian
    Wen, Qiang
    BMC CANCER, 2025, 25 (01)
  • [35] Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma
    Allo, Ghassan
    Bandarchi, Bizhan
    Yanagawa, Naoki
    Wang, Ami
    Shih, Warren
    Xu, Jing
    Dalby, Morgan
    Nitta, Hiroaki
    To, Christine
    Liu, Ni
    Sykes, Jenna
    Tsao, Ming S.
    HISTOPATHOLOGY, 2014, 64 (06) : 826 - 839
  • [36] Epidermal growth factor receptor mutations in adenocarcinoma lung: Comparison of techniques for mutation detection
    Shukla, Saumya
    Pandey, Rahul K.
    Mishra, Sridhar
    Tripathi, Suryakant
    Garg, Rajiv
    Gupta, Gaurav
    Husain, Nuzhat
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022, 65 (02) : 296 - 304
  • [37] Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib
    Liam, Chong-Kin
    Ruthranesan, Muventhiran
    Lee, Chee-Hong
    Pang, Yong-Kek
    Chua, Keong-Tiong
    Lim, Boon-Khaw
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (03) : 267 - 274
  • [38] Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma
    Shi, Zhang
    Zheng, Xuan
    Shi, Ruifeng
    Song, Changen
    Yang, Runhong
    Zhang, Qianwen
    Wang, Xinrui
    Lu, Jianping
    Yu, Yongwei
    Liu, Qi
    Jiang, Tao
    SCIENTIFIC REPORTS, 2017, 7
  • [39] The Role of Adjuvant Chemotherapy for Stage II/III Lung Adenocarcinoma Based on Epidermal Growth Factor Receptor Mutation Status
    Tsutani, Y.
    Shimada, Y.
    Ito, H.
    Miyata, Y.
    Ikeda, N.
    Nakayama, H.
    Okada, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S207 - S208
  • [40] Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis
    Rau, Kun-Ming
    Chen, Han-Ku
    Shiu, Li-Yen
    Chao, Tsai-Ling
    Lo, Yi-Ping
    Wang, Chin-Chou
    Lin, Meng-Chih
    Huang, Chao-Cheng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (04)